Archives: Disease Info Pages

Diffuse Large B-Cell Lymphoma Diagnosis

Diffuse Large B-Cell Lymphoma Diagnosis

For a diagnosis of diffuse large B-cell lymphoma (DLBCL), multiple steps are required to determine the subtype, stage of disease, and the extent to which tissues and organ systems are involved. Besides a complete physical examination, the initial evaluation includes documentation of the patient’s medical and family history, current medications, comorbidities, and current signs and…

Diffuse large B-cell lymphoma Prognosis

Diffuse large B-cell lymphoma Prognosis

Diffuse large B-cell lymphoma (DLBCL) is the most common type of lymphoma, comprising around 25% to 30% of all cases of non-Hodgkin lymphoma (NHL). The disease usually presents with a rapidly growing mass or enlarged lymph nodes in nodal or extranodal sites.1  For individuals with a recent diagnosis of DLBCL, there is considerable heterogeneity in…

Diffuse Large B-Cell Lymphoma Etiology

Diffuse Large B-Cell Lymphoma Etiology

Diffuse large B-cell lymphoma (DLBCL) is an aggressive type of cancer that originates within the lymphatic system. It has the potential to spread easily to multiple organ systems and tissues. Accounting for approximately 30% to 40% of cases of non-Hodgkin lymphoma (NHL), DLBCL is the most common subtype of NHL.1 DLBCL results from the unregulated…

DLBCL Epidemiology

Diffuse Large B-Cell Lymphoma Epidemiology

Diffuse large B-cell lymphoma (DLBCL) is a type of cancer that originates in and affects the lymphatic system.1 It is the most common type of non-Hodgkin lymphoma (NHL), accounting for approximately 31% of NHL cases in Western countries and around 37% of B-cell tumors globally.2   Incidence Rate of DLBCL Between 1970 and 1995, the incidence…

Diffuse large B-cell lymphoma

Diffuse Large B-Cell Lymphoma Overview

Diffuse large B-cell lymphoma (DLBCL) is the most common cancer of the lymphatic system, comprising approximately 30% to 40% of cases of non-Hodgkin lymphoma (NHL).1,2 In DLBCL, B cells, a type of white blood cell, become abnormal and infiltrate tissues and organs in a widespread, diffuse pattern.3 Because of its rapid growth rate involving multiple…

hATTR treatment guidelines

Hereditary Transthyretin Amyloidosis Guidelines

Hereditary transthyretin amyloidosis (hATTR) is a rare and autosomal dominant disease characterized by the accumulation of amyloid protein in several organs due to changes in the transthyretin (TTR) gene.1,2 Amyloid protein can typically build up in the nerves, heart, eyes, and gastrointestinal tract, leading to multiple signs and symptoms. Peripheral neuropathy (neuropathic pain, numbness in…

hATTR prognosis

Hereditary Transthyretin Amyloidosis Prognosis

Hereditary transthyretin-mediated amyloidosis (hATTR) is a rare, inherited, progressive, degenerative, physically debilitating, and fatal disease caused by mutations in the transthyretin (TTR) gene that lead to misfolding of the transthyretin protein. This results in the deposition of insoluble, misassembled amyloid fibrils in various organs and tissues of the body that disrupt normal tissue structure and…

hATTR patient education

Hereditary Transthyretin Amyloidosis Patient Education

Hereditary transthyretin amyloidosis (hATTR) is a rare genetic disease in which protein amyloid accumulates in several organs and tissues of the body.1 Depending on which organ is affected, patients can present with different signs and symptoms. Most commonly, hATTR can greatly affect the nerves of the peripheral nervous system, leading to numbness of the hands,…

Hereditary transthyretin amyloidosis (hATTR) complications

Hereditary Transthyretin (hATTR) Amyloidosis Complications

Hereditary transthyretin (hATTR) amyloidosis is a rare systemic disorder associated with mutations in the transthyretin (TTR) gene, in which abnormal proteins (amyloid) accumulate in various organs and tissues, impairing function. As the disease progresses, the symptoms become more severe. If hATTR is not treated, serious complications may result. Early detection and intervention are essential to…

hereditary transthyretin (hATTR) amyloidosis treatment

Hereditary ATTR Amyloidosis Treatment

The treatment of hereditary transthyretin (hATTR) amyloidosis focuses primarily on inhibiting the formation and deposition of amyloid protein aggregates, managing symptoms, and monitoring involved organ systems. Organ transplant is used in cases of advanced disease and organ failure.1 Anti-amyloid Therapies Anti-amyloid therapies are divided into 2 main categories: transthyretin (TTR)-stabilizing therapies and gene-silencing therapies.1  TTR…